EUCTR2013-005577-43-Outside-EU/EEA进行中（未招募）1 期
A phase III, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age in healthy infants in Russia. - DTPA-IPV (INFANRIX-IPV)-061
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 235
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects’ parent(s)/adoptive parent(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female child between 3 and 4 months of age at the time of the first vaccination.
- •Written informed consent obtained from the parents/adoptive parent(s) of the subject prior to performing any study specific procedure.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Born full-term
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 235
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Child in care
- •Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period.
- •Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- •Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting since birth. For corticosteroids, this will mean prednisone >= 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •Administration of long-acting immune-modifying drugs at any time during the study period
- •Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine administration, with the exception of hepatitis B and other vaccines given as part of the national immunisation schedule and as part of routine vaccination practice, that are allowed at any time during the study period. Seasonal or pandemic influenza vaccine can be given at any time during the study, and according to the Summary of Product Characteristics and national recommendations.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
- •Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis and Hib diseases.
- •History of diphtheria, tetanus, pertussis, poliomyelitis and Hib diseases.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Family history of congenital or hereditary immunodeficiency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •Major congenital defects.
- •Serious chronic illness.
- •History of any neurological disorders or seizures.
- •Acute disease and/or fever at the time of enrolment.
- •- Fever is defined as temperature >= 37.5°C for oral, axillary or tympanic route, or >= 38.0°C for rectal route.
- •- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
研究者
相似试验
进行中（未招募）
不适用
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of ageHealthy infants greater than or equal to 46 days and less than or equal to 74 days of age on the day of inclusionMedDRA version: 16.0Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069543Term: Hemophilus influenzae type b immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 100000004865EUCTR2012-004221-25-ESSanofi Pasteur MSD385
尚未招募
3 期
A Phase III Study to Evaluate the Immunogenicity and Safety of Typbar TCV Typhoid Vaccine in Adults greater than 65 Years.CTRI/2024/06/069638Bharat Biotech International Limited
已完成
4 期
Study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, or in previous receipt of the AS03B adjuvanted H1N1 (2009)Topic: Children, Primary CareSubtopic: All Diagnoses, Not AssignedDisease: All Diseases, All DiseasesInfections and InfestationsISRCTN11725083Health Protection Agency (HPA) (UK)254
进行中（未招募）
1 期
Assessing responses to annual nasal flu vaccine in children who have or have not previously been given pandemic flu vaccine.EUCTR2013-003592-35-GBPublic Health England254
已完成
3 期
A clinical study on Pentavalent vaccineCTRI/2015/06/005837Shantha Biotechnics Private Limited1,040